Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay

Abstract

The OHP assay is a simple, inexpensive global test that is useful for assessing patients with hypercoagulable states including APLA. OHP results are significantly abnormal in hypercoagulable groups compared with controls, indicating that both increased fibrin generation and reduced fibrinolysis contribute to hypercoagulable states. The assay may ultimately assist in tailoring clinical management to patients' individual requirements.

Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives

“…10 Data on links between clot properties and VTE are sparse. Curnow et al 11 showed that hypercoagulable patients with arterial thrombosis or VTE, pregnancy complications, or autoimmune diseases have increased fibrin generation and reduced fibrinolysis. It has been demonstrated that increased D-dimer levels indicating enhanced fibrin formation and degradation represent an independent risk factor for future VTE.…”

Fibrin Clot Structure and Function

“…Curnow et al showed that hypercoagulable patients with arterial thrombosis or VTE, pregnancy complications, or autoimmune diseases have increased fibrin generation and reduced fibrinolysis. 131 Several studies documented reduced efficiency of clot lysis in VTE patients. Hypofibrinolysis has been shown in subjects following the first deep-vein thrombosis episode.…”

The Means of Progress in Improving the Results of in vitro Fertilization Based on the Identification and Correction of the Pathology of Hemostasis

“…Relationship between the predisposition to intravascular coagulation (thrombophilia) and unsuccessful ART results is actively discussed in current publications; however, mechanisms to produce the impact that increases thrombotic readiness on IVF are not absolutely clear. It is reported that women with thrombophilia may have increased risks for spontaneous abortion, preclinical pregnancy loss and recurrent implantation failure (Christiansen et al, 2006;Coulam et al, 2006b;Curnow et al, 2006;Many et al, 2001;Seghatchian et al, 1996;Stern & Chamley, 2006;Urman et al, 2005;Wichers et al, 2009;Younis et al, 2000). Presently, most studied and prevalent thrombophilias include APS and such risk factors as hereditary antithrombin III deficiency, factor V Leiden mutation, prothrombin mutation, polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene, plasminogen activator inhibitor-1 (PAI-1), fibrinogen, platelet glycoproteins ITGA2, ITGB3, and some others.…”

“…Besides, a number of researchers raise a great interest in the decrease of fibrinolytic blood activity, which is often detected in recurrent miscarriages, APS, deep vein thrombosis of lower extremities, oral contraceptive intake, myocardial infarction, and malignant neoplasms (Bertina, 1997;Birkenfeld et al, 1994;Curnow et al, 2006;Dmowski et al, 1995;Egbase et al, 1999;Lisman et al, 2005;Meltzer et al, 2009;Meltzer et al, 2010;Triplett, 1989;Wichers et al, 2009). The system of fibrinolysis, as well as the system of coagulation, is a complex system which gives characteristics to fibrinolytic responses and its central element that plays role in the activation of plasminogen into plasmin.…”